 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| Quinvaxem (diphtheria, Tetanus, whole-cell pertussis- HiB - HepB) / GSK
Journal, Adverse events: Intussusception and Other Adverse Event Surveillance after Pilot Introduction of Rotavirus Vaccine in Nam Dinh and Thua Thien Hue Provinces-Vietnam, 2017-2021. (Pubmed Central) - Feb 24, 2024
Significantly higher AEFI rates occurred among children given Rotavin-M1 with pentavalent vaccines (Quinvaxem
- | Quinvaxem (diphtheria, Tetanus, whole-cell pertussis- HiB - HepB) / GSK
Journal: Immunogenicity of the pentavalent DTwP-HB-Hib vaccine (Shan-5) used in the Thai Expanded Program on Immunization compared to the hexavalent DTaP-HB-Hib-IPV and DTwP-HB-Hib (Quinvaxem) vaccines administered to infants at 2, 4, 6 (Pubmed Central) - Jun 14, 2023
The immunogenicity of the HepB surface antigen in the EPI Shan-5 vaccine was similar to that achieved by the hexavalent vaccine, but was higher than that achieved by the Quinvaxem vaccine. The Shan-5 vaccine is highly immunogenic and generates robust antibody responses after primary immunization.
- || Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis,adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK, Quinvaxem (diphtheria, Tetanus, whole-cell pertussis- HiB - HepB) / GSK
Clinical, Journal: Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. (Pubmed Central) - Apr 28, 2021
P4
The Shan-5 vaccine is highly immunogenic and generates robust antibody responses after primary immunization. Vaccination with a TT-containing and/or the Tdap vaccine during pregnancy did not compromise the seroprotection rate achieved following primary and booster immunization in individuals receiving either the pentavalent or hexavalent vaccine.
- | Trial completion: Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand (clinicaltrials.gov) - Oct 24, 2019
P4, N=370, Completed, Sponsor: Universiteit Antwerpen
Vaccination with a TT-containing and/or the Tdap vaccine during pregnancy did not compromise the seroprotection rate achieved following primary and booster immunization in individuals receiving either the pentavalent or hexavalent vaccine. Recruiting --> Completed
- |||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK, Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK, Quinvaxem (diphtheria, Tetanus, whole-cell pertussis- HiB - HepB) / GSK
Enrollment open: Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand (clinicaltrials.gov) - May 27, 2015
P4, N=300, Recruiting, Sponsor: Universiteit Antwerpen
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK, Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK, Quinvaxem (diphtheria, Tetanus, whole-cell pertussis- HiB - HepB) / GSK
New P4 trial: Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand (clinicaltrials.gov) - Apr 6, 2015
P4, N=300, Not yet recruiting, Sponsor: Universiteit Antwerpen
- ||||||| Quinvaxem (diphtheria, Tetanus, whole-cell pertussis- HiB - HepB) / GSK
Trial completion: A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject (clinicaltrials.gov) - Jul 15, 2014
P3, N=400, Completed, Sponsor: Crucell Holland BV
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Quinvaxem (diphtheria, Tetanus, whole-cell pertussis- HiB - HepB) / GSK
Enrollment closed: A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject (clinicaltrials.gov) - Feb 5, 2014
P3, N=400, Active, not recruiting, Sponsor: Crucell Holland BV
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Quinvaxem (diphtheria, Tetanus, whole-cell pertussis- HiB - HepB) / GSK
New P3 trial: A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject (clinicaltrials.gov) - Aug 4, 2013
P3, N=400, Active, not recruiting, Sponsor: Crucell Holland BV
- |||| Quinvaxem (diphtheria, Tetanus, whole-cell pertussis- HiB - HepB) / GSK
Trial completion: Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination (clinicaltrials.gov) - Jul 17, 2012
P4, N=400, Completed, Sponsor: Crucell Holland BV
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Quinvaxem (diphtheria, Tetanus, whole-cell pertussis- HiB - HepB) / GSK
Trial completion: Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B (clinicaltrials.gov) - Sep 14, 2011
P3, N=131, Completed, Sponsor: Crucell Holland BV
Active, not recruiting --> Completed Active, not recruiting --> Completed